Stephen Palmer
Professor

Profile

Biography

Stephen Palmer is a Professor and Deputy Director of TEEHTA. He has worked in economic evaluation for over 15 years in areas including pharmaceuticals, cardiology, cancer, mental health, diagnostic and screening programmes and policy. He has extensive experience of health economic evaluation, regulatory and reimbursement processes. His principal areas of expertise relate to the methodology and application of decision-analytic modelling and Bayesian approaches to Health Technology Assessment.  He has worked closely with policy makers and currently leads the programme of work at CHE for the National Institute for Health and Clinical Excellence (NICE) and he is also a member of the NICE Decision Support Unit.  He has advised policy makers internationally including in the USand Canada. He is currently a member of the NICE Technology Appraisal Committee and the NIHR Research for Patient Benefit Programme. 

Research

Overview

• Methodology and application of decision-analytic modelling
• Bayesian approaches to the evaluation of health technologies

Research group(s)

• Economic evaluation of health technologies

External activities

Memberships

• NICE Technology Appraisal Committee Committee member
• NICE Decision Support Unit Lead member
• The Research for Patient Benefit Programme (RfPB) Committee member 

External roles 

• External examiner for the University of Sheffield MSC – Health Economics and Decision Modelling
• Trials Steering Committee for the NIHR project – Upright maternal position in women with epidural analgesia

Editorial duties

• PharmacoEconomics Editorial board

Invited talks and conferences

• Skeletal care academy
  Paris, 12-13 March 2010
  Cancer related burden of disease: the burden of illness (plenary session)
• National Institute for Health and Clinical Excellence
  London, November 2009
  Filling in the evidence gaps fairly – the use of evidence synthesis approaches to incorporating indirect evidence.
• Health Protection Agency Annual Conference
  Warwick, UK, September 14-16, 2009.
  The value of evidence in reducing uncertainty (symposium session).
• US National Research Council Committee
  Washington, 22 October 2008
  Decision analysis and the value of information for ranking FDA product categories based on health consequences.
• Canadian Agency for Drugs and Technologies in Health (CADTH)
  Ottawa, October 2008
  Meeting the requirements of decision makers: approaches to evidence synthesis and cost-effectiveness analysis